Iovance Biotherapeutics
IOVA
85 hedge funds and large institutions have $429M invested in Iovance Biotherapeutics in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 13 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
23% more capital invested
Capital invested by funds: $349M → $429M (+$79.3M)
1% more funds holding
Funds holding: 84 → 85 (+1)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0.69% more ownership
Funds ownership: 76.4% → 77.09% (+0.69%)
30% less call options, than puts
Call options by funds: $178K | Put options by funds: $254K
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$19.3M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.6M |
| 3 |
Millennium Management
New York
|
+$10.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$5.38M |
| 5 |
JP Morgan Chase
New York
|
+$4.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$10.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.56M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$4.04M |
| 4 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$693K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$524K |
IOVA Hedge Fund Activity: Q3 2017 in Review
85 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2017, worth a combined $429M — up 23% from $349M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IOVA positions and 13 closed out — a net gain of 1 holder — while 37 added to existing stakes and 20 trimmed.
The largest buyer was OrbiMed, adding an estimated $19.3M. The largest seller was BlackRock, cutting an estimated $10.1M.
- 85 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2017, up from 84 in Q2 2017.
- Funds reported $429M of Iovance Biotherapeutics stock for Q3 2017, up 23% quarter-over-quarter.
- 14 funds opened new Iovance Biotherapeutics positions in Q3 2017 and 13 closed out, a net change of +1 holder.
- The largest Iovance Biotherapeutics buyer in Q3 2017 was OrbiMed, an estimated $19.3M added.
- The largest Iovance Biotherapeutics seller in Q3 2017 was BlackRock, an estimated $10.1M sold.
Based on aggregated 13F filings for Q3 2017.